Global Oral Nonsteroidal Anti-Inflammatory Drugs Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

 Oral Nonsteroidal Anti-Inflammatory Drugs Market Size

• The global oral nonsteroidal anti-inflammatory drugs market size was valued at USD 23.19 billion in 2024 and is expected to reach USD 36.57 billion by 2032, at a CAGR of 5.86% during the forecast period
• This growth is driven by factors such as the rising prevalence of chronic pain and inflammatory conditions, along with increasing demand for non-opioid pain management solutions

Oral Nonsteroidal Anti-Inflammatory Drugs Market Analysis

• Oral NSAIDs are commonly used for relieving pain, reducing inflammation, and managing fever in conditions such as arthritis, musculoskeletal injuries, and menstrual cramps
• The market is primarily driven by the increasing prevalence of chronic pain disorders, growing geriatric population, and rising demand for non-opioid pain management alternatives
• North America is expected to dominate the oral nonsteroidal anti-inflammatory drugs market due to advanced healthcare infrastructure, high awareness about pain management, and strong presence of pharmaceutical companies
• Asia-Pacific is expected to be the fastest growing region in the oral nonsteroidal anti-inflammatory drugs market during the forecast period due to increasing healthcare access, expanding middle-class population, and rising incidence of chronic conditions
• The arthritis segment is expected to dominate the market with a market share of 38.5%, attributed to high global prevalence of osteoarthritis and rheumatoid arthritis, particularly among the aging population

Report Scope and Oral Nonsteroidal Anti-Inflammatory Drugs Market Segmentation

Oral Nonsteroidal Anti-Inflammatory Drugs Market Trends

“Shift Towards Over-the-Counter (OTC) Availability and Personalized Pain Management”

• One prominent trend in the oral nonsteroidal anti-inflammatory drugs market is the growing shift towards over-the-counter (OTC) availability, driven by consumer demand for easier access to pain management solutions without the need for prescriptions
• This trend is enhancing patient autonomy, providing a convenient and cost-effective option for managing common conditions such as arthritis, muscle pain, and headaches
  • For instance, OTC formulations of NSAIDs such as ibuprofen and naproxen are gaining popularity, offering fast-acting relief with lower risk of dependency compared to opioids
• These trends are transforming pain management, empowering patients to take control of their health while driving the demand for more personalized and accessible oral NSAID options

Oral Nonsteroidal Anti-Inflammatory Drugs Market Dynamics

Driver

“Rising Prevalence of Chronic Pain and Inflammatory Conditions””

• The increasing prevalence of chronic pain and inflammatory disorders such as osteoarthritis, rheumatoid arthritis, lower back pain, and sports injuries is a major driver of the oral NSAIDs market
• These conditions are particularly common among aging populations, as well as individuals with sedentary lifestyles, contributing to a sustained demand for effective and accessible pain relief options
• As awareness of non-opioid alternatives grows, more patients and healthcare providers are turning to NSAIDs as a safer option for long-term pain management

For instance,

• In July 2023, the World Health Organization reported that musculoskeletal conditions are the leading contributor to disability worldwide, affecting approximately 1.71 billion people, with low back pain being the single leading cause 
• As a result, the growing burden of chronic pain and inflammation across global populations is fueling increased adoption of oral NSAIDs, driving market expansion

Opportunity

“Expanding Applications of AI in Drug Discovery and Personalized NSAID Therapy”

• The integration of artificial intelligence (AI) in drug discovery is creating new opportunities for the development of more targeted and safer NSAID formulations, optimizing pain management for individual patients
• AI-powered models can analyze patient data, predict responses to various NSAIDs, and recommend the most effective dosage with minimal side effects, advancing the concept of personalized medicine in pain therapy
• In addition, AI can accelerate clinical trials by identifying suitable patient cohorts and predicting drug efficacy, thereby reducing development time and improving regulatory success rates

For instance,

• In September 2024, a study published in Nature Medicine highlighted how AI algorithms can help identify biomarkers for drug response in inflammatory conditions, enabling tailored NSAID treatment plans and minimizing adverse effects such as gastrointestinal and cardiovascular risks 
• By leveraging AI for personalized treatment strategies, pharmaceutical companies can improve patient satisfaction, reduce trial-and-error prescribing, and unlock significant growth potential in the oral NSAIDs market

Restraint/Challenge

“Gastrointestinal and Cardiovascular Side Effects Limiting Long-Term Use”

• One of the major challenges in the oral NSAIDs market is the risk of adverse side effects, particularly gastrointestinal bleeding, ulcers, and cardiovascular complications associated with prolonged use
• These risks can lead to reduced patient adherence, the need for co-prescription of protective agents (e.g., proton pump inhibitors), and hesitancy among healthcare providers to prescribe NSAIDs for long-term treatment
• Such safety concerns also lead to increased regulatory scrutiny, labeling requirements, and in some cases, restricted use among high-risk populations, which can impact overall market expansion

For instance,

• In October 2023, the U.S. FDA updated safety warnings on NSAIDs, highlighting an increased risk of heart attack and stroke with long-term use, particularly in patients with pre-existing heart conditions, reinforcing the need for cautious prescribing practices 
• Consequently, these safety-related challenges can limit the widespread adoption of oral NSAIDs, driving demand for alternative therapies and affecting the market’s growth potential

Oral Nonsteroidal Anti-Inflammatory Drugs Market Scope

The market is segmented on the basis of disease indication, drugs, end user and distribution channel.

In 2025, the Arthritis is projected to dominate the market with a largest share in Disease Indication segment

The Arthritis surgery segment is expected to dominate the Oral Nonsteroidal Anti-Inflammatory Drugs market with the largest share of 38.5% in 2025 due to high global incidence of osteoarthritis and rheumatoid arthritis, especially among the elderly population. Oral NSAIDs remain the preferred first-line treatment due to their efficacy in managing chronic inflammation and pain, contributing to consistent demand and market growth

The Retail Pharmacy is expected to account for the largest share during the forecast period in Distribution Channel

In 2025, the Retail Pharmacy segment is expected to dominate the market with the largest market share of 46.39% due to its extensive distribution network and accessibility to consumers. Factors contributing to this dominance include the increasing demand for over-the-counter medications and the rising trend of self-medication among patients. Retail pharmacies offer a wide range of pharmaceutical products, ensuring convenience and prompt service, which enhances customer satisfaction.

Oral Nonsteroidal Anti-Inflammatory Drugs Market Regional Analysis

“North America Holds the Largest Share in the Oral Nonsteroidal Anti-Inflammatory Drugs Market”

• North America dominates the global oral nonsteroidal anti-inflammatory drugs market due to well-established healthcare infrastructure, high prevalence of chronic pain conditions such as arthritis and migraines, and the presence of leading pharmaceutical companies
• U.S. holds a significant share, driven by its aging population, which has a higher incidence of arthritis and other musculoskeletal disorders. The increasing demand for OTC NSAIDs also supports market growth in the region
• The High healthcare spending, advanced research and development initiatives by key players, and the extensive availability of oral NSAIDs in both prescription and over-the-counter forms strengthen the market further
• In addition, the growing trend toward self-medication and the preference for oral administration due to its convenience and effectiveness in managing pain contribute to North America's market dominance

“Asia-Pacific is Projected to Register the Highest CAGR in the Oral Nonsteroidal Anti-Inflammatory Drugs Market”

• Asia-Pacific is expected to experience the highest growth rate in the oral NSAIDs market, driven by rapid healthcare infrastructure expansion, increasing healthcare access, and a growing awareness of pain management options
• Countries such as China, India, and Japan are emerging as key markets due to their large populations, rising prevalence of chronic pain conditions, and an increasing focus on healthcare reform
• Japan's advanced medical technology and strong pharmaceutical industry also contribute to the growth of oral NSAIDs, particularly for the treatment of arthritis and other age-related conditions
• India's increasing access to healthcare, coupled with the rising geriatric population, further boosts the demand for pain relief medications, including oral NSAIDs. The government's initiatives to improve healthcare infrastructure and affordability are key factors in the market's expansion in the region

Oral Nonsteroidal Anti-Inflammatory Drugs Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

Bayer AG ,Pfizer Inc ,Reckitt Benckiser ,Novartis AG ,DAIICHI SANKYO COMPANY, LIMITED. ,Zydus Group ,Lupin ,GSK plc. ,GLENMARK PHARMACEUTICALS LTD. ,Amneal Pharmaceuticals LLC

AstraZeneca

Johnson & Johnson Services Inc.

Merck & Co. Inc.

AbbVie Inc.

Sanofi

Amgen Inc.

Cipla Ltd.

Intas Pharmaceuticals Ltd.

Alkem

Panacea Biotec

Hikma Pharmaceuticals PLC

Latest Developments in Global Oral Nonsteroidal Anti-Inflammatory Drugs Market

• In January 2025, Pfizer announced the launch of its new combination oral NSAID, Aptisolve, in the European Union, following approval from the European Medicines Agency (EMA). Aptisolve is a novel formulation designed to provide enhanced pain relief for patients suffering from osteoarthritis and rheumatoid arthritis
• In October 2024, Johnson & Johnson unveiled a new extended-release formulation of Ibuprofen XR at the American College of Rheumatology (ACR) Annual Meeting. This new formulation provides patients with longer-lasting pain relief, reducing the need for frequent dosing, and improving adherence. The drug is primarily aimed at patients with chronic conditions such as osteoarthritis and ankylosing spondylitis, with a focus on reducing gastrointestinal side effects commonly associated with traditional NSAIDs
• In September 2024, Bayer Pharmaceuticals launched its Nexaflex oral NSAID for the treatment of acute pain associated with sports injuries and muscle strains. The product was introduced in North America and is marketed as a safer, more effective alternative to traditional NSAIDs. Nexaflex is designed to provide rapid pain relief while minimizing the risk of gastrointestinal irritation, making it an ideal option for athletes and active individuals
• In September 2024, GlaxoSmithKline (GSK) announced the acquisition of a new NSAID technology from a biopharmaceutical startup that enhances the effectiveness of ibuprofen while reducing adverse effects on the gastrointestinal system
• In May-2022, Dr. Reddy's Laboratories released Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market. This product is a nonsteroidal anti-inflammatory drug (NSAID) recommended for the short-term management of moderately serious acute pain, that offers analgesia at the opioid stage and used only as continuation treatment after intravenous or intramuscular dosing of ketorolac tromethamine, if necessary 

SKU-56360